Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
GenFleet Therapeutics-B (02595.HK): Pan RAS Inhibitor GFH276 Has Independent IP with No Risk of Similar Infringement or Trade Secret Disputes
Recommend 3 Positive 2 Negative 2 |
||||
|
||||
|
GenFleet Therapeutics-B (02595.HK) stated that it recently noted certain reports regarding letters issued by RevMed to third-party companies concerning patent and trade secret disputes related to RAS inhibitors. In a clarification announcement, GenFleet Therapeutics said that the entities, products and disputed matters mentioned in RevMed's letters are unrelated to the company. GenFleet's Pan RAS inhibitor GFH276 possesses fully independent and self-originated intellectual property rights, and there is no risk of similar infringement or trade secret disputes. GenFleet has established a comprehensive global patent portfolio for its Pan RAS inhibitor project. The patent covering the compound structure of GFH276 was officially published on March 6 last year, with patent protection expected to last until 2044. (sl/da) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
